Clinical Edge Journal Scan

No prognostic impact of PMRT in pT1-2 BC tumors with N1 lymph node metastases


 

Key clinical point: Postmastectomy radiotherapy (PMRT) did not influence locoregional recurrence (LRR) in patients with pT1-2 and 1-3 node-positive breast cancer (BC).

Major finding: Rate of LRR at 5 years was similar in patients receiving PMRT and no PMRT ( P = .61), and PMRT was not significantly associated with LRR in the overall population ( P = .305).

Study details: Findings are from a retrospective, cohort study including 8914 patients with pT1-2 BC tumors and 1-3 lymph node metastases who received PMRT (n = 492) or no PMRT (n = 8422) after undergoing mastectomy and axillary lymph node dissection.

Disclosures: This study was supported by the Japanese Breast Cancer Society. Some authors declared receiving speaker’s fees, consulting fees, research funds, or honoraria from several sources.

Source: Yamada A et al. Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1–3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry. Eur J Cancer. 2022;172:32-40 (Jun 22). Doi: 10.1016/j.ejca.2022.05.017

Recommended Reading

Study confirms BRCA1 and BRCA2 linked to seven cancers
MDedge Hematology and Oncology
Select patients with breast cancer may skip RT after lumpectomy
MDedge Hematology and Oncology
Amazon involved with new cancer vaccine clinical trial
MDedge Hematology and Oncology
Hormone therapy didn’t increase recurrence or mortality in women treated for breast cancer
MDedge Hematology and Oncology
HER2-low metastatic BC: Phase 3 establishes trastuzumab deruxtecan as a new standard-of-care
MDedge Hematology and Oncology
DBT lowers risk for advanced BC diagnosis in women with dense breasts and at high risk
MDedge Hematology and Oncology
Concurrent use of DOAC and tamoxifen does not increase hemorrhage risk in BC
MDedge Hematology and Oncology
HER2-negative metastatic BC: First-line nivolumab, bevacizumab, paclitaxel shows promise in phase 2
MDedge Hematology and Oncology
Breast cancer: Etoricoxib reduces taxane-associated acute pain syndrome
MDedge Hematology and Oncology
HER2+ early BC: Atezolizumab fails to improve pCR rate in phase 3
MDedge Hematology and Oncology